| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma, Open-Angle | 8 | 2025 | 15 | 1.900 |
Why?
|
| Genome-Wide Association Study | 10 | 2024 | 106 | 1.790 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2024 | 198 | 1.680 |
Why?
|
| Genomics | 7 | 2023 | 109 | 1.220 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2025 | 176 | 1.170 |
Why?
|
| Keratosis | 2 | 2017 | 4 | 1.020 |
Why?
|
| Skin Diseases, Genetic | 2 | 2017 | 4 | 1.020 |
Why?
|
| Erythema | 2 | 2017 | 5 | 1.020 |
Why?
|
| Humans | 56 | 2025 | 14537 | 0.960 |
Why?
|
| Polymorphism, Genetic | 4 | 2011 | 99 | 0.910 |
Why?
|
| Mutation | 6 | 2014 | 306 | 0.890 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 8 | 0.770 |
Why?
|
| Biomedical Research | 3 | 2024 | 49 | 0.730 |
Why?
|
| Exfoliation Syndrome | 5 | 2021 | 12 | 0.690 |
Why?
|
| Genetic Variation | 5 | 2021 | 175 | 0.640 |
Why?
|
| Female | 30 | 2025 | 9103 | 0.640 |
Why?
|
| South Africa | 25 | 2023 | 7596 | 0.620 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 40 | 0.610 |
Why?
|
| Male | 26 | 2025 | 6754 | 0.600 |
Why?
|
| Biological Specimen Banks | 1 | 2017 | 3 | 0.570 |
Why?
|
| Eye Proteins | 2 | 2014 | 4 | 0.570 |
Why?
|
| Cytoskeletal Proteins | 2 | 2014 | 5 | 0.570 |
Why?
|
| Glycoproteins | 2 | 2014 | 10 | 0.570 |
Why?
|
| Cathepsin B | 1 | 2017 | 2 | 0.570 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 4 | 0.570 |
Why?
|
| Gene Duplication | 1 | 2017 | 13 | 0.570 |
Why?
|
| Program Development | 1 | 2017 | 32 | 0.570 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 181 | 0.550 |
Why?
|
| Middle Aged | 19 | 2025 | 3601 | 0.540 |
Why?
|
| Genetic Loci | 2 | 2021 | 11 | 0.530 |
Why?
|
| Specimen Handling | 1 | 2017 | 105 | 0.530 |
Why?
|
| Genetic Privacy | 1 | 2016 | 2 | 0.520 |
Why?
|
| Genetic Counseling | 1 | 2016 | 14 | 0.520 |
Why?
|
| Amino Acid Oxidoreductases | 4 | 2019 | 9 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2015 | 2 | 0.490 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 4 | 0.490 |
Why?
|
| Cystic Fibrosis | 3 | 2009 | 9 | 0.480 |
Why?
|
| Aged | 13 | 2025 | 1740 | 0.470 |
Why?
|
| Body Mass Index | 4 | 2025 | 321 | 0.460 |
Why?
|
| DNA Copy Number Variations | 4 | 2017 | 22 | 0.440 |
Why?
|
| Dyslipidemias | 2 | 2025 | 57 | 0.430 |
Why?
|
| Central Nervous System Depressants | 1 | 2013 | 1 | 0.420 |
Why?
|
| Ethanol | 1 | 2013 | 3 | 0.420 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2013 | 9 | 0.420 |
Why?
|
| Receptors, Corticotropin | 2 | 2003 | 2 | 0.420 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 17 | 0.420 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2009 | 2 | 0.420 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2023 | 35 | 0.420 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 19 | 0.420 |
Why?
|
| Africa | 8 | 2024 | 376 | 0.420 |
Why?
|
| Gene Rearrangement | 2 | 2009 | 15 | 0.420 |
Why?
|
| Brain | 1 | 2013 | 53 | 0.410 |
Why?
|
| Hypertension | 3 | 2023 | 419 | 0.410 |
Why?
|
| Genetics, Population | 3 | 2021 | 52 | 0.410 |
Why?
|
| Case-Control Studies | 8 | 2023 | 480 | 0.400 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2018 | 158 | 0.400 |
Why?
|
| Obesity | 3 | 2025 | 367 | 0.390 |
Why?
|
| Haplotypes | 5 | 2021 | 125 | 0.340 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2009 | 7 | 0.340 |
Why?
|
| Mutation, Missense | 2 | 2017 | 65 | 0.340 |
Why?
|
| Rheumatic Diseases | 1 | 2009 | 17 | 0.340 |
Why?
|
| Phenotype | 3 | 2025 | 158 | 0.320 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2008 | 5 | 0.310 |
Why?
|
| Adult | 12 | 2025 | 5913 | 0.300 |
Why?
|
| Risk Factors | 8 | 2025 | 1475 | 0.300 |
Why?
|
| Multifactorial Inheritance | 2 | 2025 | 9 | 0.290 |
Why?
|
| Pedigree | 3 | 2017 | 30 | 0.280 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 237 | 0.270 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2023 | 25 | 0.260 |
Why?
|
| Genetics, Medical | 3 | 2014 | 21 | 0.260 |
Why?
|
| Alleles | 5 | 2021 | 143 | 0.240 |
Why?
|
| Africa South of the Sahara | 6 | 2023 | 353 | 0.240 |
Why?
|
| Checklist | 1 | 2024 | 5 | 0.240 |
Why?
|
| Precision Medicine | 1 | 2024 | 10 | 0.240 |
Why?
|
| Cross-Sectional Studies | 6 | 2025 | 1422 | 0.230 |
Why?
|
| Life Expectancy | 1 | 2023 | 31 | 0.220 |
Why?
|
| Pigmentation | 1 | 2003 | 2 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 26 | 0.220 |
Why?
|
| Pharmacogenetics | 1 | 2023 | 31 | 0.220 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 30 | 0.220 |
Why?
|
| Postmenopause | 1 | 2023 | 11 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 32 | 0.210 |
Why?
|
| Heart Failure | 1 | 2023 | 38 | 0.210 |
Why?
|
| Aging | 1 | 2023 | 109 | 0.210 |
Why?
|
| Racism | 1 | 2022 | 4 | 0.210 |
Why?
|
| Chromosome Mapping | 3 | 2021 | 20 | 0.200 |
Why?
|
| Hair Color | 1 | 2002 | 1 | 0.200 |
Why?
|
| Genome | 1 | 2022 | 9 | 0.200 |
Why?
|
| Ethics Committees, Research | 1 | 2022 | 5 | 0.200 |
Why?
|
| Kidney | 1 | 2022 | 46 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 69 | 0.190 |
Why?
|
| DNA, Ancient | 1 | 2021 | 3 | 0.190 |
Why?
|
| Genotype | 4 | 2021 | 442 | 0.190 |
Why?
|
| Health Status | 1 | 2022 | 111 | 0.190 |
Why?
|
| Steroid Hydroxylases | 1 | 2021 | 2 | 0.190 |
Why?
|
| Human Migration | 1 | 2021 | 8 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 146 | 0.190 |
Why?
|
| Interleukin-8 | 1 | 2021 | 21 | 0.180 |
Why?
|
| Mental Health | 1 | 2022 | 91 | 0.180 |
Why?
|
| Intraocular Pressure | 2 | 2025 | 4 | 0.180 |
Why?
|
| Gene Deletion | 2 | 2011 | 19 | 0.180 |
Why?
|
| Exercise | 1 | 2023 | 205 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 468 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 14 | 0.170 |
Why?
|
| Tretinoin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 36 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2019 | 33 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2019 | 36 | 0.160 |
Why?
|
| Genetic Testing | 2 | 2023 | 34 | 0.160 |
Why?
|
| Amino Acids | 1 | 2018 | 16 | 0.160 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2018 | 7 | 0.160 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 17 | 0.160 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 16 | 0.160 |
Why?
|
| African Americans | 1 | 2018 | 47 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 260 | 0.150 |
Why?
|
| Gene Frequency | 3 | 2024 | 122 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 3 | 2024 | 17 | 0.150 |
Why?
|
| Accreditation | 1 | 2017 | 3 | 0.140 |
Why?
|
| Young Adult | 4 | 2021 | 2498 | 0.140 |
Why?
|
| Epidermis | 1 | 2017 | 1 | 0.140 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2017 | 1 | 0.140 |
Why?
|
| Norway | 1 | 2017 | 2 | 0.140 |
Why?
|
| Epigenomics | 1 | 2017 | 3 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2017 | 4 | 0.140 |
Why?
|
| Point Mutation | 1 | 2017 | 16 | 0.140 |
Why?
|
| Keratinocytes | 1 | 2017 | 2 | 0.140 |
Why?
|
| DNA Glycosylases | 1 | 2017 | 4 | 0.140 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 6 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2017 | 11 | 0.140 |
Why?
|
| Quality Control | 1 | 2017 | 27 | 0.140 |
Why?
|
| Adiposity | 1 | 2018 | 96 | 0.140 |
Why?
|
| Health Resources | 1 | 2017 | 66 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 127 | 0.130 |
Why?
|
| DNA Mutational Analysis | 4 | 2011 | 34 | 0.130 |
Why?
|
| Exons | 3 | 2012 | 17 | 0.130 |
Why?
|
| Mass Screening | 2 | 2015 | 245 | 0.130 |
Why?
|
| Urban Population | 1 | 2018 | 257 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2025 | 225 | 0.130 |
Why?
|
| Photography | 1 | 2015 | 5 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 5 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2018 | 317 | 0.130 |
Why?
|
| Prevalence | 3 | 2025 | 1192 | 0.130 |
Why?
|
| Animals | 2 | 2013 | 1081 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 253 | 0.130 |
Why?
|
| Cell Phone | 1 | 2015 | 34 | 0.120 |
Why?
|
| Telemedicine | 1 | 2015 | 25 | 0.120 |
Why?
|
| Gonioscopy | 1 | 2014 | 2 | 0.120 |
Why?
|
| Visual Fields | 1 | 2014 | 2 | 0.120 |
Why?
|
| Gene-Environment Interaction | 2 | 2024 | 12 | 0.120 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 38 | 0.120 |
Why?
|
| Genome, Human | 1 | 2014 | 25 | 0.120 |
Why?
|
| Disease | 1 | 2014 | 12 | 0.120 |
Why?
|
| Parakeratosis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 11 | 0.110 |
Why?
|
| Computational Biology | 1 | 2013 | 44 | 0.110 |
Why?
|
| Cholesterol, LDL | 2 | 2025 | 150 | 0.110 |
Why?
|
| Receptors, Melanocortin | 2 | 2003 | 2 | 0.110 |
Why?
|
| Linkage Disequilibrium | 2 | 2024 | 40 | 0.100 |
Why?
|
| Pregnancy | 2 | 2022 | 1862 | 0.100 |
Why?
|
| Kenya | 2 | 2023 | 183 | 0.100 |
Why?
|
| Connexins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Hearing Loss | 1 | 2011 | 1 | 0.090 |
Why?
|
| Sex Factors | 2 | 2023 | 227 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2011 | 31 | 0.090 |
Why?
|
| Europe | 3 | 2014 | 56 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 253 | 0.090 |
Why?
|
| United States | 2 | 2025 | 132 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2022 | 1748 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2021 | 32 | 0.080 |
Why?
|
| Tandem Repeat Sequences | 1 | 2008 | 3 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 9 | 0.080 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2008 | 35 | 0.080 |
Why?
|
| Child | 3 | 2022 | 2242 | 0.080 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2006 | 1 | 0.070 |
Why?
|
| Genetic Techniques | 1 | 2006 | 9 | 0.070 |
Why?
|
| Waist-Hip Ratio | 1 | 2025 | 29 | 0.060 |
Why?
|
| Triglycerides | 1 | 2025 | 47 | 0.060 |
Why?
|
| Genetic Heterogeneity | 1 | 2024 | 9 | 0.060 |
Why?
|
| Waist Circumference | 1 | 2025 | 60 | 0.060 |
Why?
|
| Environment | 1 | 2024 | 22 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2022 | 967 | 0.060 |
Why?
|
| HIV Infections | 1 | 2023 | 5097 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2024 | 40 | 0.060 |
Why?
|
| Telomere | 1 | 2023 | 17 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2023 | 11 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2023 | 23 | 0.060 |
Why?
|
| Gadolinium | 1 | 2023 | 5 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2023 | 5 | 0.050 |
Why?
|
| Contrast Media | 1 | 2023 | 6 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2003 | 4 | 0.050 |
Why?
|
| Research Design | 1 | 2024 | 124 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 15 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 22 | 0.050 |
Why?
|
| Liver | 1 | 2023 | 74 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2023 | 43 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 80 | 0.050 |
Why?
|
| Prognosis | 1 | 2023 | 199 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2023 | 188 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2023 | 42 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2023 | 107 | 0.050 |
Why?
|
| Human Genetics | 1 | 2022 | 2 | 0.050 |
Why?
|
| Cystatin C | 1 | 2022 | 9 | 0.050 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2023 | 108 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 53 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lipoid Proteinosis of Urbach and Wiethe | 1 | 2002 | 1 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Codon | 1 | 2002 | 7 | 0.050 |
Why?
|
| Malawi | 1 | 2022 | 87 | 0.050 |
Why?
|
| Biomarkers | 1 | 2023 | 327 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 435 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 62 | 0.050 |
Why?
|
| Heterozygote | 1 | 2002 | 43 | 0.050 |
Why?
|
| Uganda | 1 | 2022 | 197 | 0.050 |
Why?
|
| Homozygote | 1 | 2002 | 61 | 0.050 |
Why?
|
| History, Ancient | 1 | 2021 | 6 | 0.050 |
Why?
|
| Phytohemagglutinins | 1 | 2021 | 9 | 0.050 |
Why?
|
| Whole Exome Sequencing | 1 | 2021 | 3 | 0.050 |
Why?
|
| Language | 1 | 2021 | 14 | 0.050 |
Why?
|
| Anterior Chamber | 1 | 2021 | 4 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 7 | 0.050 |
Why?
|
| Community Health Workers | 1 | 2022 | 66 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 44 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 47 | 0.050 |
Why?
|
| Monocytes | 1 | 2021 | 27 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 60 | 0.050 |
Why?
|
| Africa, Southern | 1 | 2021 | 91 | 0.050 |
Why?
|
| Logistic Models | 1 | 2021 | 254 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2022 | 321 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 26 | 0.040 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 22 | 0.040 |
Why?
|
| Asia | 2 | 2014 | 72 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2019 | 79 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 48 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2017 | 3 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2017 | 6 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 3 | 0.040 |
Why?
|
| Eye | 1 | 2017 | 13 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2017 | 18 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 35 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 13 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Body Composition | 1 | 2018 | 153 | 0.030 |
Why?
|
| Incidence | 2 | 2011 | 685 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 15 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 20 | 0.030 |
Why?
|
| Glaucoma | 1 | 2015 | 1 | 0.030 |
Why?
|
| Ophthalmology | 1 | 2015 | 3 | 0.030 |
Why?
|
| Eye Diseases | 1 | 2015 | 7 | 0.030 |
Why?
|
| Zambia | 1 | 2016 | 115 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 15 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 48 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2015 | 120 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 31 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 11 | 0.030 |
Why?
|
| England | 1 | 2014 | 15 | 0.030 |
Why?
|
| Health | 1 | 2014 | 11 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2013 | 22 | 0.030 |
Why?
|
| Community Participation | 1 | 2013 | 42 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 2 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Introns | 1 | 2012 | 13 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 90 | 0.030 |
Why?
|
| Adolescent | 2 | 2011 | 2985 | 0.020 |
Why?
|
| Connexin 26 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Audiometry | 1 | 2011 | 2 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2011 | 2 | 0.020 |
Why?
|
| Hearing Tests | 1 | 2011 | 4 | 0.020 |
Why?
|
| Health Personnel | 1 | 2013 | 231 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 22 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 149 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2006 | 1 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2006 | 1 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2006 | 5 | 0.020 |
Why?
|
| Amenorrhea | 1 | 2006 | 9 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2006 | 11 | 0.020 |
Why?
|
| Testosterone | 1 | 2006 | 14 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2006 | 14 | 0.020 |
Why?
|
| Estradiol | 1 | 2006 | 18 | 0.020 |
Why?
|
| Family Health | 1 | 2006 | 16 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2002 | 1 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2002 | 9 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2002 | 60 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 77 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 1479 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 2244 | 0.010 |
Why?
|